Zentek Ltd (ZTEK) FinancialsZTEKZentek Ltd

Zentek Ltd (ZTEK) generates its revenue primarily from IP Development, which accounts for 100.0% of total sales, equivalent to CAD 36.77K. Understanding this concentration is critical for investors evaluating how ZTEK navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Zentek Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.24%, provide a clear picture of how effectively ZTEK converts its operational activities into shareholder value.

In the context of the broader market, ZTEK competes directly with industry leaders such as ATLX and LGO. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ZTEK's gross margin of N/A stands against ATLX's N/A and LGO's -6.09%. Such benchmarking helps identify whether Zentek Ltd is trading at a premium or discount relative to its financial performance.

Zentek has shown inconsistent revenue growth, with total revenue peaking at 813,596 CAD in Q4 2025 but dropping to just 6,204 CAD in Q2 2026. The gross margin has been negative for most quarters, indicating ongoing challenges in profitability.